Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® in metastatic uveal melanoma
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI - its first tissue-specific autoimmune candidate - for patients with type 1 diabetes
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® in previously treated advanced melanoma
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
QIMC Extends DDH-26-05 Drilling to Beyond 1,000 Metres and Launches In-Situ Hydrogen Characterization and Extraction Program at Bennett Hill as Seismic Further Corroborates Two Distinct Hydrogen Systems in Nova Scotia
